IN8bio

Nice work Kate!  Great discussion with Dr. Yusof about our exciting work in this area. #ACR25 #AutoimmuneDisease #GDTcells #GammaDeltaTCells #Immunotherapy #CellTherapy Md Yuzaiful Md Yusof RheumNow

IN8bio is proud to announce that The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of the INB-100, an allogeneic gamma-delta T cell therapy for patients with complex leukemia. To date this trial has demonstrated long-term remission and survival in patients with high-risk disease, with the earliest treated patients beyond 4 and 5 years relapse-free. With multiple sites screening, we look forward to completing the enrollment of the study expansion cohort and releasing follow-up data next year. Read more: https://lnkd.in/eQ9BbirY #CancerZero

IN8bio presented data demonstrating the power of INB-619, a γδ T cell Engager, to drive complete B cell depletion in preclinical Lupus (SLE) donor models. This data highlights the potential to transform the treatment of autoimmune diseases by harnessing the unique properties of γδ T cells to safely and precisely eliminate pathogenic B cells. Read more: https://lnkd.in/eCy9MyB7 #CancerZero

IN8bio Presents New T Cell Engager (TCE) Data Demonstrating Deep B Cell Depletion for Autoimmune Indications. INB-619 is a CD19-targeted, pan-γδ T cell engager designed to activate and expand γδ T cells to drive deep target cell depletion. The data is being presented today at the 2025 American College of Rheumatology (ACR) Convergence Meeting in Chicago. Read the full press release and view our virtual poster: https://lnkd.in/eCy9MyB7 #ACR25 #CancerZero

Thanks to my colleague Adrian Hayday and his group and to the editors of Science Magazine for continuing to highlight the unique properties of gamma delta T cells for their efficacy and safety in the treatment of cancer. Trials such as those conducted by IN8bio and collaborating institutions UAB Medicine and The University of Kansas Cancer Center are demonstrating how these cells can achieve success against difficult to treat cancers.

Adrian Hayday, one of the pioneers of γδ T cell biology, highlights what makes these cells so unique: their natural ability to discriminate cancer from healthy tissue. This biology is the foundation of IN8bio’s platform and why we believe γδ T cells represent the next major frontier in immunotherapy.  #CancerZero

In anticipation of our upcoming new TCE data release at ACR later this month, our COO, Kate Rochlin, PhD, will present an overview of our novel Gamma-delta T Cell Engager Program at the T-Cell Engager for Autoimmune Disease Summit in Boston on October 16th, 2025. Our unique TCE functions to both activate and expand gamma-delta T cells, driving deep target cell depletion. This exciting platform brings the power of these cells to autoimmune disease. Kate will deliver an oral presentation and participate in a panel discussion tomorrow. We hope to see you there! Learn More: https://bit.ly/3W9dzQh.

Our CEO and co-founder, William Ho, is participating in a panel discussion titled “Deal Stories – What We’ve Learned and What Comes Next” at the Fierce Biotech Summit in Boston this morning at 9:30 am EST. #FierceBiotechWeek2025 #Biotech Fierce Life Sciences Events

IN8bio is proud to attend BIO Alabama in Birmingham, home of our R&D and manufacturing facility! Our CEO & co-founder, William Ho, will present today at 9:45 a.m. CST. We are also happy to have our CSO & co-founder, Lawrence Lamb, PhD, in attendance! #BioAlabama #ALBioTech #CancerZero #IN8bio BIO Alabama

“On a scale of 1 to 10—and it’s a 12—it’s glioblastoma.”   That’s how Dr. Selwyn Vickers & CEO of Memorial Sloan Kettering Cancer Center and former Dean of Medicine at the University of Alabama at Birmingham, described just how devastating glioblastoma can be in his recent conversation with David Rubenstein on Bloomberg’s fantastic new “Longevity” series.   We’re especially proud to say that Dr. Vickers was instrumental in helping us establish our first Phase 1 glioblastoma clinical trial (INB-200) during his time at UAB. His early belief in our approach helped set the foundation for our company and clinical data.    Why is GBM so deadly? Because even a millimeter of missed tissue can mean the difference between remission and recurrence. And because you can’t just remove brain tissue; it doesn’t grow back!   Our clinical INB-200 program is designed to meet this challenge with a novel cell therapy, powered by the unique properties of gamma-delta T cells. Glioblastoma hasn’t seen meaningful clinical progress in over two decades. Our science aims to bring new hope to patients who desperately need better options. #CancerZero #GBM National Brain Tumor Society